{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.07","upperLimit":"6.67","value":"5.2"},{"comment":"Unable to Estimate due to low numbers.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"cabozantinib, 100 milligrams po QD for 12 weeks until progression or unacceptable toxicity.","id":"OG000","title":"NRE Cohort - CRPC 100 mg"},{"description":"cabozantinib, 39.4 milligrams po QD for 12 weeks until progression or unacceptable toxicity.","id":"OG001","title":"NRE Cohort - CRPC 39.4 mg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 15 months","title":"Duration of Bone Scan Response - NRE Cohorts, CRPC Only","type":"SECONDARY","unitOfMeasure":"months"}